|
1
|
Gordon PH: Amyotrophic lateral sclerosis:
An update for 2013: Clinical features, pathophysiology, management
and therapeutic trials. Aging Dis. 4:295–310. 2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kiernan MC, Vucic S, Cheah BC, Turner MR,
Eisen A, Hardiman O, Burell JR and Zoing MC: Amyotrophic lateral
sclerosis. Lancet. 377:942–955. 2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Miller RG, Mitchell JD and Moore DH:
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron
disease (MND). Cochrane Database Syst Rev.
2012(CD001447)2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Bowser B, Turner MB and Shefner J:
Biomarkers in amyothrophic lateral sclerosis: Opportunities and
limitations. Nat Rev Neurol. 7:631–638. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Li D, Shen D, Tai H and Cui L:
Neurofilaments in CSF as diagnostic biomarkers in motor neuron
disease: A metaanalysis. Front Aging Neuroscl.
8(290)2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Brooks BR: El Escorial world federation of
neurology criteria for the diagnosis of amyotrophic lateral
sclerosis. Subcommittee on motor neuron diseases/amyotrophic
lateral sclerosis of the world federation of neurology research
group on neuromuscular diseases and the El Escorial ‚clinical
limits of amyotrophic lateral sclerosis’ workshop contributors. J
Neurol Sci. 124 (Suppl):S96–S107. 1994.PubMed/NCBI View Article : Google Scholar
|
|
7
|
de Carvalho M, Dengler R, Eisen A, England
JD, Kaji R, Kimura J, Mills K, Mitsumoto H, Nodera H, Shefner J and
Swash M: Electrodiagnostic criteria for diagnosis of ALS. Clin
Neurophysiol. 119:497–503. 2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Talbot K: Motor neuron disease. Postgrad
Med J. 78:513–519. 2002.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Traynor BJ, Codd MB, Corr B, Forde C,
Frost E and Hardiman O: Amyotrophic lateral sclerosis mimic
syndromes: A population-based study. Arch Neurol. 57:109–113.
2000.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Mitsumoto H, Brooks BR and Silani V:
Clinical trials in amyotrophic lateral sclerosis: Why so many
negative trials and how can trials be improved? Lancet Neurol.
13:1127–1138. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
De Sousa EA, Chin RC, Sander HW, Latov N
and Brannigan TH III: Demyelinating findings in typical and
atypical chronic inflammatory demyelinating polyneuropathy:
Sensitivity and specificity. J Clin Neuromuscul Dis. 10:163–164.
2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hinchcliffe M and Smith A: Rilusole: Real
world evidence supports significant extension of median survival
times in patients with amyotrophic lateral sclerosis. Degener
Neurol Neuromuscul Dis. 7:61–70. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Marcu IR, Dop D, Padureanu V, Niculescu
SA, Padureanu R, Niculescu CE and Rogoveanu OC: Non-steroidal
anti-inflammatory drug etoricoxib facilitates the application of
individualized exercise programs in patients with ankylosing
spondylitis. Medicina (Kaunas). 56(270)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Masrori P and Van Damme P: Amyotrophic
lateral sclerosis: a clinical review. Eur J Neurol. 27:1918–1929.
2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
EFNS Task Force on Diagnosis and
Management of Amyotrophic Lateral Sclerosis. Andersen PM, Abrahams
S, Borasio GD, de Carvalho M, Chio A, Van Damme P, Hardiman O,
Kollewe K, Morrison KE, et al: EFNS guidelines on the clinical
management of amyotrophic lateral sclerosis (MALS)-revised report
of an EFNS task force. Eur J Neurol. 19:360–375. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Writing Group; Edaravone (MCI-186) ALS 19
Study Group. Safety and efficacy of edaravone in well defined
patients with amyotrophic lateral sclerosis: A randomised,
double-blind, placebo-controlled trial. Lancet Neurol. 16:505–512.
2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Al Chalabi A, Andersen PM, Chandran S,
Chio A, Corcia P, Couratier P, Danielsson O, de Carvalho M,
Desnuelle C, Grehl T, et al: July 2017 ENCALS statement on
edaravone. Amyotroph Lateral Scler Frontotemporal Degener.
18:471–474. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Mora JS, Genge A, Chio A, Estol CJ,
Chaverri D, Hernández M, Marín S, Mascias J, Rodriguez GE, Povedano
M, et al: Masitinib as an add-on therapy to riluzole in patients
with amyotrophic lateral sclerosis: A randomized clinical trial.
Amyotroph Lateral Scler Frontotemporal Degener. 21:5–14.
2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Jiang J, Zhu Q, Gendron TF, Saberi S,
McAlonis-Downes M, Seelman A, Stauffer JE, Jafar-Nejad P, Drenner
K, Schulte D, et al: Gain of toxicity from ALS/FTD-linked repeat
expansions in C9ORF72 is alleviated by antisense oligonucleotides
targeting GGGGCC-containing RNAs. Neuron. 90:535–550.
2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mazzini L, Mareschi K, Ferrero I, Vassallo
E, Oliveri G, Nasuelli N, Oggioni GD, Testa L and Fagioli F: Stem
cell treatment in amyotrophic lateral sclerosis. J Neurol Sci.
265:78–83. 2008.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Deda H, Inci MC, Kürekçi AE, Sav A,
Kayihan K, Ozgün E, Ustünsoy GE and Kocabay S: Treatment of
amyotrophic lateral sclerosis patients by autologous bone
marrow-derived hematopoietic stem cell transplantation: A 1-year
follow-up. Cytotherapy. 11:18–25. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Desport JC, Preux PM, Magy L, Boirie Y,
Vallat JM, Beaufrere B and Couratier P: Factors correlated with
hypermetabolism in patients with amyotrophic lateral sclerosis. Am
J Clin Nutr. 74:328–334. 2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Desport JC, Preux PM, Truong TC, Vallat
JM, Sautereau D and Couratier P: Nutritional status is a prognostic
factor for survival in ALS patients. Neurology. 53:1059–1063.
1999.PubMed/NCBI View Article : Google Scholar
|
